Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 25, 2002. The report primarily details changes in directors' interests in the company's Ordinary Shares and announces a specific share repurchase transaction.
Key Financial Metrics
The filing does not provide consolidated financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to specific share transactions:
- Share Repurchase Price: 1259.2802p per share.
- Retirement Fund ADR Average Price (Nov 21): $39.97.
- Retirement Fund ADR Average Price (Nov 22): $39.54.
Material Changes
The filing reports the following material changes regarding equity and director interests:
- Share Repurchase: On November 22, 2002, the company purchased 800,000 ordinary shares for cancellation.
- Retirement Fund Fluctuations:
- On November 21, 2002, the GlaxoSmithKline US Retirement Savings Plan's holdings decreased from 18,177,123 to 18,125,253 ADRs.
- On November 22, 2002, the Plan's holdings increased from 18,125,253 to 18,172,040 ADRs.
- Director Interests: Directors Dr. J.P. Garnier and Mr. J.D. Coombe hold interests in the shares held by the Retirement Savings Plan, consistent with other employees.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, future guidance, outlook, risk factors, or contingencies. The share repurchase was executed in accordance with authority granted by shareholders at the Annual General Meeting on May 20, 2002.
Key Facts for Investor Verification
- Verify the total number of shares repurchased for cancellation under the May 20, 2002 authorization.
- Confirm the impact of the 800,000 share repurchase on the company's total outstanding share count.
- Review the full terms of the GlaxoSmithKline US Retirement Savings Plan to understand the nature of the directors' indirect interests.
- Check subsequent filings for consolidated financial results, as this 6-K does not contain them.